Live Breaking News & Updates on Daratumumab

Stay informed with the latest breaking news from Daratumumab on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Daratumumab and stay connected to the pulse of your community

Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM

Panelists summarize key takeaways on using bispecific antibodies for multiple myeloma treatment.

Operationalizing-treatment , Multiple-myeloma , Patients , Community , Treatment-setting , Combination-therapy , Crs , Cytokine-release-syndrome , Daratumumab ,

Looking Ahead: Future Perspectives on AL Amyloidosis

Heather Landau, MD, invites panelists to provide their insights on the future outlook for the treatment of AL amyloidosis.

Vaishali-sanchorawala , Jeffrey-zonder , Heather-landau , Peer-exchange , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab , Vital , Pronto , Affirm-al , Nexicart-1

NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis

Faculty offer insights on the NEXICART-1 phase 1 clinical trial investigating the safety and efficacy of NXC-201 in patients with AL amyloidosis and discuss potential clinical implications on the study’s findings.

United-states , American , Vaishali-sanchorawala , Heather-landau , Jeffrey-zonder , Peer-exchange , American-society-of-hematology , American-society , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab

Daratumumab-Based Regimen Potential Promising Bridging Therapy for RRMM

The combination of daratumumab and immumodulatory therapy was evaluated among patients with relapsed/refractory multiple myeloma (RRMM) who have failed prior treatment with immunomodulatory agents, proteasome inhibitors, and daratumumab as monotherapy or in combination.

Dara-imi , Blood-cancer , Multiple-myeloma , Daratumumab , Imid , Relapsed-refractory-multiple-myeloma- ,

Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials

Vaishali Sanchorawala, MD, provides insights on the pooled safety analysis of data from phase 1 to 3 trials, including PRONTO and VITAL, which investigated the use of birtamimab in patients with light chain (AL) amyloidosis.

United-states , American , Vaishali-sanchorawala , Heather-landau , Jeffrey-zonder , Peer-exchange , American-society-of-hematology , American-society , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab

The Potential Role of CAR T Therapy in AL Amyloidosis

A panel of expert oncologists discuss the underlying rationale and potential role for CAR T therapy in patients with AL amyloidosis.

Heather-landau , Jeffrey-zonder , Vaishali-sanchorawala , Peer-exchange , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab , Vital , Pronto , Affirm-al , Nexicart-1

Subcutaneous daratumumab with VRd improves progression-free survival in multiple myeloma

1. Adding subcutaneous daratumumab to VRd (bortezomib, lenalidomide, and dexamethasone) induction/consolidation, and lenalidomide maintenance therapy improves progression-free survival in eligible newly diagnosed multiple myeloma patients. 2. Newly diagnosed multiple myeloma patients treated with daratumumab alongside VRd and lenalidomide maintenance therapy showed higher complete response and minimal residual disease (MRD-negative) rates. Evidence Rating Level: 1 (Excellent)

Rating-level , Daratumumab , Multiple-myeloma , Vrd , Chronic-disease , Oncology ,

AFFIRM-AL: Birtamimab in Patients with Mayo Stage IV AL Amyloidosis

A panel of expert oncologists explore the ongoing AFFIRM-AL trial, examining birtamimab in patients diagnosed with Mayo stage IV AL amyloidosis.

Transforming-outcomes , Precision-medicine , Targeted-therapies , Mayo-stage , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab , Vital , Pronto , Affirm-al

Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL

A panel of expert oncologists explore novel therapies using monoclonal antibodies designed to target amyloid deposit, highlighting key data from the VITAL study.

Transforming-outcomes , Precision-medicine , Targeted-therapies , Treatment-approaches , Abs-targeting-amyloid-deposits , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab , Vital , Pronto

ASH 2023: PERSEUS Trial Overview

Rafael Fonseca, MD, discusses findings from the PERSEUS trial presented in December at ASH 2023.

Conference-perspectives , Multiple-myeloma , American-society-of-hematology , Ash , Newly-diagnosed-multiple-myeloma- , Triplet-therapy- , Quadruplet-therapy , Perseus-trial- , Daratumumab , Bortezomib- , Lenalidomide-